Long-Term Outcome of Patients with Follicular Lymphoma Is Not Fundamentally Affected By KMT2D, EZH2, and Crebbp Mutational Status

Autor: Kurt S. Bantilan, Kayleigh Rutherford, Joseph McCarter, Noushin Farnoud, Juan E. Arango-Ossa, Elli Papaemmanuil, Andrew D. Zelenetz

Publikováno v: Blood. 140:3635-3637

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f4b1580752defbfa11ca46b78bef6a7d
https://doi.org/10.1182/blood-2022-170205

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

Autor: Meghan C. Thompson, Rosemary A. Harrup, Catherine C. Coombs, Lindsey E. Roeker, Jeffrey J. Pu, Michael Y. Choi, Paul M. Barr, John N. Allan, Martin Šimkovič, Lori Leslie, Joanna Rhodes, Elise A. Chong, Manali Kamdar, Alan Skarbnik, Frederick Lansigan, Brittany McCall, Khalid Saja, Martin J. S. Dyer, Harriet S. Walter, Marcus Lefebure, Maria Thadani-Mulero, Michelle Boyer, Juliana Biondo, Kavita Sail, Beenish S. Manzoor, Richard Furman, Kurt S. Bantilan, Andre Goy, Tatyana Feldman, Dominic Labella, Stephen J. Schuster, Jae Park, Lia Palomba, Andrew Zelenetz, Toby A. Eyre, Arnon P. Kater, John F. Seymour, Anthony R. Mato

Publikováno v: Blood, 6(15), 4553-4557. American Society of Hematology
Blood advances, 6(15), 4553-4557. American Society of Hematology
Thompson, M C, Harrup, R A, Coombs, C C, Roeker, L E, Pu, J J, Choi, M Y, Barr, P M, Allan, J N, Simkovi, M, Leslie, L, Rhodes, J, Chong, E A, Kamdar, M, Skarbnik, A, Lansigan, F, McCall, B, Saja, K, Dyer, M J S, Walter, H S, Lefebure, M, Thadani-Mulero, M, Boyer, M, Biondo, J, Sail, K, Manzoor, B S, Furman, R, Bantilan, K S, Goy, A, Feldman, T, Labella, D, Schuster, S J, Park, J, Palomba, L, Zelenetz, A, Eyre, T A, Kater, A P, Seymour, J F & Mato, A R 2022, ' Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen ', Blood, vol. 6, no. 15, pp. 4553-4557 . https://doi.org/10.1182/bloodadvances.2022007812

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5788d2dcc76be1604266c786b4beeb47
https://research.vumc.nl/en/publications/dcf1cfe8-7b8c-4df5-b481-6746476ba1c1

The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma

Autor: Thaís Fischer, Andy Ni, Kurt S. Bantilan, Jacob D. Soumerai, Anna Alperovich, Connie Batlevi, Anas Younes, Andrew D. Zelenetz

Publikováno v: Leukemialymphoma. 63(3)

Although treatment with anti-CD20 monoclonal antibodies (mAb) has improved outcomes in B-cell malignancies, it's associated with increased risk of hypogammaglobulinemia (HG). Our study aimed to determine the effects of anti-CD20 mAb on serum immunogl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39d891185ce368f0c546891b06b8ab3a
https://pubmed.ncbi.nlm.nih.gov/35109746

Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma

Autor: Steven M. Horwitz, Kimiteru Ito, Heiko Schöder, Kurt S. Bantilan, Neha Mehta-Shah, Craig S. Sauter, Alison J. Moskowitz

Publikováno v: Blood Advances. 3:187-197

The prognosis of peripheral T-cell lymphoma (PTCL) is heterogenous. Baseline or interim imaging characteristics may inform risk-adapted treatment paradigms. We identified 112 patients with PTCL who were consecutively treated with cyclophosphamide, do

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37d56b232e434bfa09aa1b186ff7e335
https://doi.org/10.1182/bloodadvances.2018024075

Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglobulin Gene Next-Generation Sequencing in a Phase 2 Study of Sequential Chemoradioimmunotherapy Followed by Autologous Stem-Cell Rescue

Autor: A. Park, T. Willis, Kurt S. Bantilan, Malek Faham, Audrey Hamilton, John F. Gerecitano, S.F. Schoninger, Carol S. Portlock, Paul A. Hamlin, Allison P. Jacob, Craig S. Sauter, K.A. Kong, M. Matasar, Ariela Noy, Gary A. Ulaner, Anita Kumar, Craig H. Moskowitz, Carla Casulo, Ravinder K. Grewal, Andrew D. Zelenetz, Maria Lia Palomba, Anas Younes

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 21:230-237.e12

Background Minimal residual disease (MRD) monitoring has been used to identify early molecular relapse and predict clinical relapse in mantle cell lymphoma (MCL). Few published data exist in MCL on the performance of next-generation sequencing–base

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56f0739caedad149691ba7983be6fe96
https://doi.org/10.1016/j.clml.2020.09.007